Compared to Estimates, Pacira (PCRX) Q4 Earnings: A Look at Key Metrics

Core Insights - Pacira (PCRX) reported revenue of $187.25 million for the quarter ended December 2024, reflecting a 3.3% increase year-over-year, with EPS at$ 0.91 compared to $0.89 in the same quarter last year [1] - The reported revenue was slightly below the Zacks Consensus Estimate of$ 187.31 million, resulting in a surprise of -0.03%, while the EPS exceeded the consensus estimate of $0.86 by 5.81% [1] Revenue Breakdown - Net product sales for iovera were$ 6.45 million, surpassing the estimated $6.36 million, marking a 6.9% increase year-over-year [4] - Net product sales for EXPAREL reached$ 147.68 million, exceeding the average estimate of $145.33 million, representing a 2.6% year-over-year growth [4] - Total net product sales amounted to$ 187.25 million, compared to the average estimate of $183.38 million, indicating a 4.2% year-over-year increase [4] - Net product sales for ZILRETTA were$ 33.12 million, exceeding the estimated $30.72 million, with a year-over-year change of 15.4% [4] Stock Performance - Over the past month, Pacira's shares have returned -2.1%, slightly better than the Zacks S&P 500 composite's -2.2% change [3] - The stock currently holds a Zacks Rank 1 (Strong Buy), suggesting potential outperformance against the broader market in the near term [3]